Contributors
DM drafted the manuscript. AM conceived, and coordinated subsequent
edits and revisions. MS and TR participated in drafting the manuscript
and its finalization. All authors have read and approved the final
manuscript.
Table 1 Disproportionality analysis (reporting odds ratio
[ROR] and its 95% confidence
interval [CI]) of selected cancers and total neoplasms for
omalizumab in VigiBase for
the period between 2000 and 2020 according to gender.